Sildenafil Citrate: Clinical Pharmacology and Safety Guide
Sildenafil Citrate is an approved phosphodiesterase type 5 (PDE5) inhibitor authorised by the MHRA in the UK for the management of erectile dysfunction. By blocking the breakdown of cyclic GMP, it enhances nitric oxide-mediated smooth muscle relaxation to improve penile blood flow safely and effectively.
Core Chemical and Pharmacological Profile
| Parameter | Clinical Specification |
|---|---|
| Active Substance / Salt | Sildenafil Citrate |
| IUPAC / Chemical Class | Pyrazolopyrimidinone |
| Pharmacological Category | PDE5 Inhibitor (phosphodiesterase type 5 inhibitor) |
| ATC Code | G04BE03 |
| Bioavailability | Approximately 41% absolute bioavailability |
| Plasma Protein Binding | 96% bound to plasma proteins |
| Elimination Half-Life (t½) | 3 to 5 hours |
| Primary Clearance Route | Hepatic (liver) metabolism via CYP3A4 |
| UK Regulatory Status | POM (Prescription-Only Medicine) / P (Pharmacy) |
Mechanism of Action and Pharmacodynamics
Sexual stimulation releases nitric oxide (a natural chemical messenger) into erectile tissue. Sildenafil Citrate blocks PDE5 (an enzyme that breaks down blood vessel relaxants). This action preserves cGMP (a molecule that helps keep smooth muscle relaxed).
Blood vessels are able to dilate as a result of relaxed smooth muscle. Increased blood flow fills the tissue, producing a firm erection. Without sexual arousal, this treatment has no effect.
Pharmacokinetics (PK) Summary
Sildenafil Citrate is absorbed quickly into the bloodstream after swallowing. Full absorption is achieved within 30 to 120 minutes when the tablet is taken on an empty stomach.
High-fat meals, however, can delay this absorption by up to one hour.
Distribution of the medicine occurs broadly throughout the body. Plasma proteins (proteins in the blood) bind 96% of the active substance.
The liver breaks down Sildenafil Citrate using CYP3A4 enzymes (liver proteins).
The body excretes 80% through faeces and 13% through urine. Its elimination half-life (t½, time for drug levels to halve) is 3 to 5 hours.
Approved Clinical Indications
Sildenafil Citrate is authorised for adult men with erectile dysfunction (difficulty getting an erection).
The standard recommended starting dose is 50mg taken before planned sexual activity.
Depending on effectiveness, your dose may be adjusted by healthcare professionals to either 25mg or 100mg.
UK reference brand Viagra contains the identical active ingredient.
Lower starting doses are recommended for individuals with hepatic impairment (reduced liver function). Dose adjustments also apply to severe renal impairment (reduced kidney function).
Contraindications and Drug Interactions
Never take Sildenafil Citrate with organic nitrates (medicines for chest pain). Combining them causes a sudden, dangerous drop in blood pressure. People with a recent history of stroke or heart attack must avoid this medicine.
Inform your prescriber if you take alpha-blockers (medicines for high blood pressure). CYP3A4 inhibitors (antifungal or antibiotic medicines) can also alter drug levels.
Before starting treatment, a qualified doctor or pharmacist should always be consulted. Avoid unapproved high-dose imports without UK regulatory clearance.
Compliance and Legal Status
Prescription-Only Medicine (POM) formulations of Sildenafil Citrate require a valid NHS or private prescription. Qualified prescribers must evaluate patient suitability before issuing a prescription. Patients must access treatment responsibly through authorised pharmacy channels.
Never seek access without appropriate clinical assessment.
Accessing Treatment Safely
In the UK, Sildenafil Citrate is regulated by the MHRA. A valid NHS or private prescription, issued by a UK prescriber, is a requirement for the supply of any Prescription-Only Medicine (POM). Pharmacy (P) medicines may be dispensed over the counter after completing a healthcare screening questionnaire. A GPhC-registered pharmacist oversees this consultation process.
Adverse Effects Profile
Sildenafil Citrate has a defined side-effect profile that requires patient awareness.
| Frequency | Side Effects |
|---|---|
| Common | Headache (pain in the head) |
| — | Facial flushing (sudden skin redness and warmth) |
| — | Dyspepsia (indigestion or stomach discomfort) |
| — | Nasal congestion (blocked nose) |
| — | Visual distortion (temporary blue tint to vision) |
| Uncommon | Somnolence (excessive sleepiness) |
| — | Tinnitus (ringing in the ears) |
| — | Vertigo (spinning sensation) |
| — | Palpitations (racing or fluttering heartbeat) |
| Rare/Serious | Priapism (painful erection lasting longer than four hours) |
| — | Sudden decrease or loss of hearing |
| — | NAION (non-arteritic anterior ischaemic optic neuropathy, causing sudden vision loss) |
| — | Severe cutaneous reactions (serious skin rash or peeling) |
Adverse Reaction Reporting
Healthcare professionals and patients should report suspected adverse drug reactions (ADRs) directly to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app.
Clinical References and Citations
- National Institute for Health and Care Excellence (NICE) Guidelines: Erectile dysfunction. https://cks.nice.org.uk/topics/erectile-dysfunction/
- NCBI: Clinical pharmacology of sildenafil citrate.
Medical Disclaimer
This piece exists purely to inform and cannot stand in for the guidance of a medical professional. Always consult a registered healthcare professional before starting or changing any treatment. Prescription-Only Medicines (POMs) are supplied strictly subject to a successful medical consultation.